Facial paresis after fludarabine treatment for advanced chronic lymphocytic leukaemia

This case report discusses a case with advanced-stage chronic lymphocytic leukaemia (CLL) that presented with facial paresis after fludarabine treatment. A 68-year old patient with CLL (Rai classification, stage IV) was admitted to Gülhane Military Medical Academy for treatment. Fludarabine, 30 mg/m...

Full description

Saved in:
Bibliographic Details
Published in:Haematologia 2002-01, Vol.32 (3), p.287-290
Main Authors: Kaptan, Kürşat, Nevruz, Oral, Çetin, Türker, Satar, Bülent, Beyan, Cengiz
Format: Article
Language:English
Subjects:
Aged
Bell's palsy
chronic lymphocytic leukaemia
facial paralysis
Facial Paralysis - chemically induced
Facial Paralysis - etiology
Fatal Outcome
Female
fludarabine
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell - complications
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
neurotoxicity
Shock, Septic - drug therapy
Shock, Septic - etiology
Vidarabine - adverse effects
Vidarabine - analogs & derivatives
Vidarabine - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This case report discusses a case with advanced-stage chronic lymphocytic leukaemia (CLL) that presented with facial paresis after fludarabine treatment. A 68-year old patient with CLL (Rai classification, stage IV) was admitted to Gülhane Military Medical Academy for treatment. Fludarabine, 30 mg/m2 daily for 5 days, was given. Right facial paresis was observed at day 8 after administration of fludarabine. The general and psychiatric condition of the patient in myelosuppression did not permit aetiological investigation for paresis. Thereafter, the patient died due to septic shock. Possible aetiological reasons why the patient being treated for advanced-stage CLL had facial paresis after the administration of fludarabine ended are discussed.
ISSN:0017-6559
1568-5594
DOI:10.1163/15685590260461110